Case Report

Spinal Metastasis as the Initial Manifestation of a Nonsecretory Glucagonoma

Authors: Anjana Aggarwal, MD, Jennifer Brainard, MD, Daniel J. Brotman, MD

Abstract

Glucagonomas are rare functional endocrine tumors of the pancreas that classically present with symptoms of glucagon excess, including rash, hyperglycemia, diarrhea, and weight loss. Metastatic disease at presentation is common but is often limited to the liver and regional lymph nodes. We describe an unusual case of a patient with glucagonoma who presented with a pathologic vertebral fracture. This tumor had no evidence of active hormone secretion but tested positive for glucagon by immunohistochemical staining.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Chastain MA. The glucagonoma syndrome: A review of its features and discussion of new perspectives. Am J Med Sci 2001; 321: 306–320.
 
2. Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV. The glucagonoma syndrome: Clinical and pathologic features in 21 patients. Medicine (Baltimore) 1996; 75: 53–63.
 
3. Barazzoni R, Zanetti M, Tiengo A, Tessari P. Protein metabolism in glucagonoma. Diabetologia 1999; 42: 326–329.
 
4. Prinz RA, Dorsch TR, Lawrence AM. Clinical aspects of glucagon-producing islet cell tumors. Am J Gastroenterol 1981; 76: 125–131.
 
5. Reyes-Govea J, Holm A, Aldrete JS. Response of glucagonomas to surgical excision and chemotherapy: Report of two cases and review of the literature. Am Surg 1989; 55: 523–527.
 
6. Patel N, Chiang P, Krasnow AZ, Carrera GF, Komoroski RA, Isitman AT, et al. Skeletal metastasis of malignant glucagonoma mimicking avascular necrosis of the hip: Scintigraphic and MRI correlation. Clin Nucl Med 1993; 18: 70–72.
 
7. Staren ED, Steinecker GA, Gould VE. A glucagon-secreting pancreatic alpha islet cell tumor presenting as spinal cord compression. J Surg Oncol 1987; 35: 249–252.
 
8. Boden G. Glucagonomas and insulinomas. Gastroenterol Clin North Am 1989; 18: 831–845.
 
9. Hashimoto M, Watanabe G, Nakamura T, Kajiyama Y, Tsurumaru M. Clinically silent pancreatic glucagonomas discovered in resected specimens by immunohistochemistry. Surgery 1997; 122: 632–633.
 
10. Mozell E, Stenzel P, Woltering EA, Rosch J, O'Dorisio TM. Functional endocrine tumors of the pancreas: Clinical presentation, diagnosis, and treatment. Curr Probl Surg 1990; 27: 301–386.
 
11. Haga Y, Yanagi H, Urata J, Inada M, Shimada S, Nitahata N, et al. Early detection of pancreatic glucagonoma. Am J Gastroenterol 1995; 90: 2216–2223.
 
12. De Giorgio R, Migliori M, Lalli S, Montini GC, Gullo L, Corinaldesi R, et al. Asymptomatic glucagonoma presenting with an isolated hepatic nodule. Hepatogastroenterology 1998; 45: 1093–1096.
 
13. Hainsworth JD, Johnson DH, Greco FA: Poorly differentiated neuroendocrine carcinoma of unknown primary site: A newly recognized clinicopathologic entity. Ann Intern Med 1988; 109: 364–371.
 
14. Kirshbom PM, Kherani AR, Onaitis MW, Feldman JM, Tyler DS. Carcinoids of unknown origin: Comparative analysis with foregut, midgut, and hindgut carcinoids. Surgery 1998; 124: 1063–1070.
 
15. O'Byrne KJ, Goggins MG, McDonald GS, Daly PA, Kelleher DP, Weir DG. A metastatic neuroendocrine anaplastic small cell tumor in a patient with multiple endocrine neoplasia type 1 syndrome: Assessment of disease status and response to doxorubicin, cyclophosphamide, etoposide chemotherapy through scintigraphic imaging with 111In-pentetreotide. Cancer 1994; 74: 2374–2378.
 
16. Friesen SR, Hermreck AS, Mantz FA Jr. Glucagon, gastrin, and carcinoid tumors of the duodenum, pancreas, and stomach: Polypeptide “apudomas” of the foregut. Am J Surg 1974; 127: 90–101.